Latest filing published 07 Aug 2026 for OKYO Pharma Ltd, €25k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Flavio Mantelli discloses dealings in OKYO Pharma Ltd to SEC (Form 4). In total, 2 filings cover trades dated 21 July 2026.
No open-market sale appears; the market trades are 1 purchase worth €25k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant.
Most recently, on 7 August 2026, the filings show an open-market purchase worth €25k in OKYO Pharma Ltd. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations